La Jolla Lupus Treatment LJP 394 Tradenames Could Include Luarc, Ipsilar
This article was originally published in Pharmaceutical Approvals Monthly
La Jolla Pharmaceutical may be considering Bentrela, Ipsilar, Luarc and Sprinza as names for its systemic lupus erythematosus (SLE) treatment LJP 394. The San Diego-based firm submitted the names to the Patent & Trademark Office for antibody-mediated diseases, including SLE.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class